Alpha memo: adaptation / training bounded update

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reset the scope to either compare SGLT2i vs Metformin explicitly or focus on a single compound across different settings.
2. Correct the misidentification of the drug in Receipt 1.

Major issues

• The memo suffers from a critical anchor mismatch and internal contradiction. The title and synthesis mention 'metformin', but Receipt 1 is explicitly about SGLT2 inhibitors (dapagliflozin).
• The central claim is that a signal from Receipt 1 does not transfer to Receipt 2, but the two receipts are testing entirely different pharmacological interventions (SGLT2i vs Metformin) and different endpoints (insulin sensitivity/VO2 max vs proinsulin). Comparing them to establish a 'translation boundary' for a single intervention is logically flawed.
• The synthesis incorrectly attributes the findings of Receipt 1 to 'metformin' in the bounded contrast and interpretation sections, despite the source bundle and the receipt's own title identifying the drug as an SGLT2 inhibitor.

Reviewer note

The manuscript is fundamentally flawed due to a failure in anchor alignment. It attempts to draw a 'translation boundary' between two studies that are not testing the same intervention. Receipt 1 investigates SGLT2 inhibitors (dapagliflozin), while Receipt 2 investigates a multimodular therapy including metformin. The author repeatedly refers to the 'adaptation / training / metformin' comparison, effectively ignoring that Receipt 1 is not about metformin. Because the central claim relies on a contrast between two different drugs, the 'alpha' is materially unsupported and the synthesis is incoherent.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis